Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death

American Journal of Epidemiology

Volumn 175, Issue 5, 2012, Pages 381-390

  Cole, Stephen R ^a   Hudgens, Michael G ^a   Tien, Phyllis C ^b,c   Anastos, Kathryn ^d,e   Kingsley, Lawrence ^f   Chmiel, Joan S ^g   Jacobson, Lisa P ^h  

^a IL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

acquired immunodeficiency syndrome; case cohort studies; cohort studies; confounding bias; HIV; pharmacoepidemiology; selection bias

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; COHORT ANALYSIS; CONFIDENCE INTERVAL; COST-BENEFIT ANALYSIS; DISEASE INCIDENCE; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; NUMERICAL MODEL; PRECISION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MONTE CARLO METHOD; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; SELECTION BIAS; UNITED STATES;

UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857566961     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr346     Document Type: Article

References (43)

1. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11 (5):550-560.
2. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of non-randomized treatments. J Am Stat Assoc. 2001;96:440-448.
3. VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. Epidemiology. 2009;20 (1):18-26.
4. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc (B). 1972;34 (2):187-220.
5. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11 (5):561-570.
6. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol. 2002;155 (11):1045-1053.
7. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158 (7):687-694.
8. Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 2005;366 (9483):378-384.
9. Mantel N. Synthetic retrospective studies and related topics. Biometrics. 1973;29 (3):479-486.
10. Kupper LL, McMichael AJ, Spirtas R. Hybrid epidemiologic study design useful in estimating relative risk. J Am Stat Assoc. 1975;70 (351):524-528.
11. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103 (2):226-235.
12. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73 (1):1-11.
13. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of casecohort designs. J Clin Epidemiol. 1999;52 (12):1165-1172.
14. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal. 1999;5 (2):99-112.
15. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150 (4):327-333.
16. Månsson R, Joffe MM, Sun W, et al. On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol. 2007;166 (3):332-339.
17. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126 (2):310-318.
18. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9 (2):117-125.
19. Lamarca R, Alonso J, Gómez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci. 1998;53 (5):M337-M343.
20. Wang MC, Brookmeyer R, Jewell NP. Statistical models for prevalent cohort data. Biometrics. 1993;49 (1):1-11.
21. Cole SR, Jacobson LP, Tien PC, et al. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. Am J Epidemiol. 2010;171 (1):113-122.
22. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126 (12):946-954.
23. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. HIV-CAUSAL Collaboration. AIDS. 2010;24 (1):123-137.
24. White HA. A heteroskedasticity-consistent covariance matrix estimator and a direct test of heteroskedasticity. Econometrica. 1980;48 (4):817-838.
25. Cole SR, Hernán MA, Anastos K, et al. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNAviral load using a marginal structural left-censored mean model. Am J Epidemiol. 2007;166 (2):219-227.
26. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168 (6):656-664.
27. Borgan O, Samuelsen SO. A review of cohort sampling designs for Cox's regression model: potentials in epidemiology. Nor Epidemiol. 2003;13 (2):239-248.
28. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50 (4):1064-1072.
29. Langholz B, Jiao J. Computational methods for case-cohort studies. Comput Stat Data Anal. 2007;51 (8):3737-3748.
30. Kulathinal S, Karvanen J, Saarela O, et al. Case-cohort design in practice-experiences from the MORGAM Project. Epidemiol Perspect Innov. 2007;4:15. (doi:10.1186/1742-5573-4-15).
31. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000;152 (10):923-933.
32. Cole SR, Hernán MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005;162 (5):471-478.
33. Breslow NE, Lumley T, Ballantyne CM, et al. Improved Horvitz-Thompson estimation of model parameters from two-phase stratified samples: applications in epidemiology. Stat Biosci. 2009;1 (1):32. (doi:10.1007/s12561-009-9001-6).
34. Breslow NE, Lumley T, Ballantyne CM, et al. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol. 2009;169 (11):1398-1405.
35. White JE. A two stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol. 1982;115 (1):119-128.
36. Walker AM. Anamorphic analysis: sampling and estimation for covariate effects when both exposure and disease are known. Biometrics. 1982;38 (4):1025-1032.
37. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60 (7):578-586.
38. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology. 2009;20 (1):3-5.
39. Westreich D, Cole SR. Invited commentary: positivity in practice. Am J Epidemiol. 2010;171 (6):674-677.
40. Hernán MA. Invited commentary: hypothetical interventions to define causal effects-afterthought or prerequisite? Am J Epidemiol. 2005;162 (7):618-620.
41. Hernán MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes (Lond). 2008;32(suppl 3): S8-S14.
42. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry DA, eds. Statistical Models in Epidemiology, the Environment, and Clinical Trials. New York, NY: Springer Publishing Company; 2000:95-133.
43. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121 (3):465-471.